Immune response by biological response modifiers.

Area of Science:

• Immunology
• Hematology
• Pharmacology

Background:

• Biological response modifiers (BRMs) can modulate immune and hematopoietic functions.
• Cyclophosphamide is a chemotherapeutic agent known for its myelosuppressive and immunosuppressive effects.

Purpose of the Study:

• To investigate the impact of BRMs on myelopoiesis and effector cell activity.
• To explore the role of colony-stimulating factor (CSF) in mediating these effects.
• To assess the potential of BRM-induced CSF to counteract chemotherapy-induced myelosuppression.

Main Methods:

• Administration of various BRMs in vivo.
• Assessment of bone marrow cellularity and granulocyte-macrophage colony-forming cells (GM-CFU-C).
• Measurement of CSF production and serum titers.
• Evaluation of immune cell activity (macrophage and natural killer cells).
• Assessment of cyclophosphamide's effects and the counteracting potential of BRMs.

Main Results:

• BRMs significantly increased myelopoiesis, evidenced by higher bone marrow cellularity and GM-CFU-C counts.
• BRM administration led to enhanced macrophage (M phi) and natural killer (NK) cell activity.
• Increased CSF production and secretion by M phi and bone marrow cells were observed following BRM treatment.
• BRM-induced CSF effectively counteracted the myelosuppressive and immunosuppressive effects of cyclophosphamide.
• In vivo CSF induced by BRMs achieved higher and more sustained titers compared to exogenous CSF.

Conclusions:

• BRMs stimulate myelopoiesis and immune effector cell functions through increased CSF production.
• BRM-induced CSF offers a promising strategy to mitigate chemotherapy-related side effects.
• Endogenous CSF generation via BRMs provides a more sustained therapeutic effect than exogenous administration.